Portfolio Rapha Capital Management

Bellicum Pharmaceuticals, Inc.: Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant

By Kevin SlawinDecember 1, 2018February 4th, 2021No Comments

Bellicum Pharmaceuticals, Inc.
Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
Experience to date in clinical study shows high clinical response rates for patients with visceral GvHD or GvHD that was refractory to standard of care treatment
December 1, 2018

Previous PostBellicum Pharmaceuticals, Inc.: Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018
Next PostPoseida Therapeutics: FDA Grants Poseida’s P-BCMA-101 Regenerative Medicine Advanced Therapy (RMAT) Status for Treatment of Multiple Myeloma

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions